These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7495079)

  • 1. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
    Takiguchi Y; Asai F; Wada K; Nakashima M
    Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2.
    Takiguchi Y; Wada K; Nakashima M
    Thromb Haemost; 1992 Oct; 68(4):460-3. PubMed ID: 1448780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis.
    Pratico D; Murphy NP; Fitzgerald DJ
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1178-85. PubMed ID: 9190851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
    Roux SP; Tschopp TB; Kuhn H; Steiner B; Hadváry P
    J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
    Cook NS; Bruttger O; Pally C; Hagenbach A
    Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.
    Matsuno H; Uematsu T; Umemura K; Takiguchi Y; Wada K; Nakashima M
    Br J Pharmacol; 1992 Jul; 106(3):533-8. PubMed ID: 1387025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
    Lynch JJ; Cook JJ; Sitko GR; Holahan MA; Ramjit DR; Mellott MJ; Stranieri MT; Stabilito II; Zhang G; Lynch RJ
    J Pharmacol Exp Ther; 1995 Jan; 272(1):20-32. PubMed ID: 7815334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
    Mousa SA; Forsythe MS; Diemer M; Bozarth JM; Reilly TM
    Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model.
    Nishiyama H; Umemura K; Saniabadi AR; Takiguchi Y; Uematsu T; Nakashima M
    Eur J Pharmacol; 1994 Oct; 264(2):191-8. PubMed ID: 7851482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
    Higo K; Karasawa A; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1251-5. PubMed ID: 1815525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
    Azzam K; Cissé-Thiam M; Drouet L
    Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo.
    Murphy NP; Pratico D; Fitzgerald DJ
    J Pharmacol Exp Ther; 1998 Aug; 286(2):945-51. PubMed ID: 9694954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery.
    Kaida T; Matsuno H; Niwa M; Kozawa O; Miyata H; Uematsu T
    Thromb Haemost; 1997 Mar; 77(3):562-7. PubMed ID: 9066011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction.
    Kerins DM; Shuh M; Kunitada S; Fitzgerald GA; Fitzgerald DJ
    J Pharmacol Exp Ther; 1991 Apr; 257(1):487-92. PubMed ID: 1708425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo inhibition of acute platelet-dependent thrombosis in a baboon model by Bay U3405, a thromboxane A2-receptor antagonist.
    Kotzé HF; Lamprecht S; Badenhorst PN; van Wyk V; Roodt JP; Alexander K
    Thromb Haemost; 1993 Oct; 70(4):672-5. PubMed ID: 8115994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of middle cerebral artery thrombosis by novel glycoprotein IIb/IIIa antagonist FK419 in guinea pig.
    Moriguchi A; Mihara K; Aoki T; Maeda M; Tojo N; Matsuoka N; Mutoh S
    Eur J Pharmacol; 2004 Sep; 498(1-3):179-88. PubMed ID: 15363993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
    Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M
    Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.